Compilation of cost-effectiveness evidence for different heart conditions and treatment strategies

Nathalie Eckard1, Magnus Janzon, Lars-Åke Levin

  • 1Center for Medical Technology Assessment, Division of Health Care Analysis, Linköping University, Sweden. nathalie.eckard@liu.se

Insights

This study compiles cost-effectiveness ratios for heart disease treatments, offering practical data for resource allocation. The findings aid decision-makers in optimizing cardiovascular healthcare investments.

Area of Science:

  • Health Economics
  • Cardiovascular Medicine
  • Public Health Policy

Background:

  • Limited accessible data exists on the cost-effectiveness of cardiovascular disease treatments.
  • Decision-makers require practical economic evidence for resource allocation in cardiology.
  • Health economic research is crucial for managing scarce healthcare resources.

Purpose of the Study:

  • To present comprehensive cost-effectiveness ratios for heart disease treatments.
  • To create a practical data set for cardiovascular healthcare decision-makers.
  • To facilitate informed resource allocation in the cardiovascular field.

Main Methods:

  • Systematic literature search for cost-effectiveness analyses of cardiovascular interventions.
  • Compilation of cost-effectiveness ratios (cost per Quality Adjusted Life Year or life year gained).
  • Categorization of data into a readily available cost-effectiveness ranking table by disease group.

Main Results:

  • Cost-effectiveness ratios varied widely, from dominant (cost-saving) to over 1,000,000 Euros per Quality Adjusted Life Year gained.
  • A categorized table of cost-effectiveness ratios and bibliographic references was generated.
  • The data covers various heart conditions and treatment strategies.

Conclusions:

  • Cost-effectiveness ranking tables effectively present health economic evidence.
  • This compilation provides valuable, concise information for healthcare resource allocation decisions.
  • The study offers an extensive overview of health economic evidence for cardiovascular disease treatment.
Abstract

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...